Acute Cerebral Ischemia
2
Pipeline Programs
3
Companies
3
Clinical Trials
0
Approved Products
Pipeline by Development Stage
Preclinical
Phase 1
Phase 1/2
Phase 2
Phase 2/3
Phase 3
On Market
0
0
0
0
0
2
0
Early DiscoveryClinical DevelopmentMarket
Drug Modality Breakdown
Peptide
3100%
Competitive Landscape
3 companies ranked by most advanced pipeline stage
Trial Timeline
Clinical trial activity over time
2021
2022
2023
2024
2025
2026
2027
2028
PharmazzSovateltide
PharmazzSovateltide
NoNONerinetide
Clinical Trials (3)
Total enrollment: 906 patients across 3 trials
Study to Assess the Safety and Efficacy of Sovateltide in Patients With Acute Cerebral Ischemic Stroke
Start: Jan 2024Est. completion: Dec 2026160 patients
Phase 4Active Not Recruiting
Sovateltide for the Treatment of Acute Traumatic Brain Injury
Start: Dec 2026Est. completion: Mar 2028214 patients
Phase 3Not Yet Recruiting
Field Randomization of Nerinetide (NA-1) Therapy in Early Responders
Start: Mar 2015Est. completion: Mar 2023532 patients
Phase 3Completed
Phase Legend
Preclinical— Lab & animal studies
Phase 1— Safety & dosing
Phase 2— Efficacy testing
Phase 3— Large-scale trials
On Market— Approved & available
Key Insights
2 late-stage (Phase 3) programs, potential near-term approvals
3 companies competing in this space
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.